BERGENBIO ASA: INVITATION TO THIRD QUARTER 2020 RESULTS
Bergen, Norway, 3 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the third quarter 2020 on Tuesday 17 November 2020. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET. The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished. The third quarter report and presentation will be